DBV snags a ‘breakthrough’ tag for its peanut allergy drug

French biotech DBV Technologies picked up the FDA’s coveted breakthrough-therapy designation for its in-development peanut allergy patch, promising a speedy review as it works toward Phase III.

Source: www.fiercebiotech.com

---